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COVID-19 caused by the SARS-CoV-2 virus is a fast emerging disease with deadly
consequences. The pulmonary system and lungs in particular are most prone to
damage caused by the SARS-CoV-2 infection, which leaves a destructive footprint in
the lung tissue, making it incapable of conducting its respiratory functions and resulting
in severe acute respiratory disease and loss of life. There were no drug treatments
or vaccines approved for SARS-CoV-2 at the onset of pandemic, necessitating an
urgent need to develop effective therapeutics. To this end, the innate RNA interference
(RNAi) mechanism can be employed to develop front line therapies against the virus.
This approach allows specific binding and silencing of therapeutic targets by using
short interfering RNA (siRNA) and short hairpin RNA (shRNA) molecules. In this review,
we lay out the prospect of the RNAi technology for combatting the COVID-19. We
first summarize current understanding of SARS-CoV-2 virology and the host response
to viral entry and duplication, with the purpose of revealing effective RNAi targets.
We then summarize the past experience with nucleic acid silencers for SARS-CoV,
the predecessor for current SARS-CoV-2. Efforts targeting specific protein-coding
regions within the viral genome and intragenomic targets are summarized. Emphasizing
non-viral delivery approaches, molecular underpinnings of design of RNAi agents are
summarized with comparative analysis of various systems used in the past. Promising
viral targets as well as host factors are summarized, and the possibility of modulating the
immune system are presented for more effective therapies. We place special emphasis
on the limitations of past studies to propel the field faster by focusing on most relevant
models to translate the promising agents to a clinical setting. Given the urgency to
address lung failure in COVID-19, we summarize the feasibility of delivering promising
therapies by the inhalational route, with the expectation that this route will provide
the most effective intervention to halt viral spread. We conclude with the authors’
perspectives on the future of RNAi therapeutics for combatting SARS-CoV-2. Since
time is of the essence, a strong perspective for the path to most effective therapeutic
approaches are clearly articulated by the authors.
Keywords: drug delivery, siRNA, COVID-19, SARS-CoV-2, anti-viral drugs
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BRIEF INTRODUCTION
Coronavirus Disease 2019 (COVID-19) caused by a new form
of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV),
named SARS-CoV-2, is a fast emerging infectious disease with
deadly consequences. The original SARS-CoV epidemic that
spread in 2002–2004 is estimated to affect ∼8400 individuals
with fatality rate of 11%, while the current epidemic has affected
3.5 M individuals with ∼305,000 loss of life as of May 15, 2020
(Figure 1A). The SARS-CoV-2 is spreading much faster but with
lower mortality rates, although exact nature of the pandemic and
the associated loss of life will likely be better analyzed after the
passage of initial pandemic. The SARS-CoV-2 appears to enter
cells via widely expressed cell-surface angiotensin−converting
enzyme 2 (ACE2) and displays strong tropism against certain
critical organs, in particular airways and lungs, kidneys and
gastrointestinal track (Guo et al., 2008). Failure of the pulmonary
and/or associated cardiovascular system is a critical factor for
loss of live among the most affected patients. Other contributing
factors are known to exasperate the disease and loss of life
(Zheng et al., 2020). Beyond the virus-associated pathology
in lung tissues, excessive pro-inflammatory response displayed
against the CoV, mediated by elevated inflammatory cytokines
and chemokines, lead to lung injury and acute respiratory distress
syndrome (ARDS). However, other notable pathologies have
been observed, including neurological complication, clotting
disorders and kidney and liver failures, whose severity and
consequences are just beginning to be understood.
The dynamic nature of COVID-19 makes it difficult to predict
future therapeutic developments in the field but, given the
significant loss of life, extreme measures are needed to minimize
patient mortality. There were no effective anti-viral therapies at
the present time to combat this infection. The fastest approach
to therapy is to re-purpose the currently approved drugs to fight
the disease, while a permanent solution could be an effective
vaccine. Major efforts are placed in this direction with promising
early results (Scavone et al., 2020). The re-purposed drugs could
be directed to viral replication events (e.g., inhibitors of unique
viral enzymes), or to host factors related to viral trafficking (e.g.,
inhibitors of endocytosis or viral escape). Alternatively, drugs
against the adverse events could be deployed to minimize the
undesirable consequences of viral host response, so that the
patients are given a chance to contain the virus. The players
in “cytokine response” have attracted attention in this regard
(Jamilloux et al., 2020) and “neutralizing” antibodies are being
actively re-positioned for this end. Like re-purposed drugs, it will
take some guess work to choose the right target for neutralization.
The know-how build with the original SARS-CoV endemic
might guide the efforts for therapeutic development. Early data
is emerging on the similarities between the SARS-CoV and
SARS-CoV-2 (Yan et al., 2020), but differences are bound to
take longer to be revealed. The inherent assumption is that the
similarities out-weight the differences between the two CoVs
and that effective therapeutics are likely to emerge from the past
knowledge on CoV infections.
Developing new small molecule drugs may be challenging,
including the time and effort required for drug development,
in case current “re-purposed” drugs are proven ineffective.
A promising approach to develop a more specific anti-viral
therapy could be based on endogenous RNA interference
(RNAi) mechanism whose physiological goal is to regulate
protein synthesis events. RNAi has been adopted for therapy
by silencing desired genes based on blockage and degradation
of corresponding mRNAs. RNAi can be implemented with
synthetic short interfering RNAs (siRNAs; 19–27 nucleotide long
double-stranded RNAs), or in situ production of short hairpin
RNAs (shRNAs) through typically plasmid DNA (pDNA)-based
expression vectors. While the latter relies on nuclear targeting for
efficient expression, siRNAs can be delivered to cytoplasmic space
to engage the RNA-induced silencing complex (RISC) directly
with minimal processing by host cells. Silencing a wide range
of targets with RNAi are being effectively implemented at will,
so that a broad therapy platform could be envisioned in this
pursuit. The exciting possibilities with RNAi was recently (2018)
confirmed with the FDA-approval of the first siRNA based drug
(Patisiran by Alnylam) to treat the nerve damage caused by
the rare disease hereditary transthyretin-mediated amyloidosis
(hATTR) in adults. Developing RNAi based drugs for SARS-
CoV-2 will be a lengthier process than the re-purposed, already
approved drugs but it is likely to offer more specific therapies.
Past attempts to control SARS-CoV infections using RNAi
may guide the efforts in the current pandemic. Unfortunately,
due to relatively small cases associated with SARS-CoV and
especially being localized to the eastern hemisphere, not so
much attention was paid to using RNAi for management of the
disease (Figure 1B); from our analysis of Pubmed publications,
deployment of RNAi in SARS remained only at a fraction of
the cancer therapy.
In this review article, we first present a concise summary of
the known infection mechanism by SARS-CoV, assuming that the
current SARS-CoV-2 follows a similar pattern of cellular entry,
trafficking and replication. The emphasis is to reveal possible
RNAi targets rather than providing a complete picture of the
associated events. We refer the reader to other sources in this
Research Theme for a more comprehensive analysis of cellular
entry mechanisms. We then review the available literature on the
use of RNAi for understanding and control of CoV infection.
We briefly outline the possible targets, industrial activity and
academic efforts, with special emphasis on the critical aspects
of the technology for clinical translation including drug delivery
issues. We additionally analyze the feasibility of employing RNAi
to control the pathogenic “cytokine storm” and finish with a
review of inhalational technology that can be applied to nucleic
acid therapies. Others have reviewed the RNAi approach to CoV
treatment (Wu and Chan, 2006) and we refer the reader to
these articles for a complementary view on the potential of RNAi
mechanism for control of CoV infections.
MECHANISM OF CELL ENTRY AND
INFECTION FOR SARS-COV-2
SARS-CoV-2 is a betacoronavirus of the family Coronaviridae
(Gordon et al., 2020). It is an enveloped, positive-sense,
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FIGURE 1 | (A) Number of deaths associated with SARS-CoV vs SARS-CoV-2 (as of May 15, 2020). Data from World Health Organization. (B) Number of Pubmed
publications on “siRNA and cancer” and “siRNA and SARS” between 2000 and 2010. The relative numbers of published papers in the two field is indicative of
relative emphasis of deploying the newly emerging RNAi technology in cancer and SARS CoV infections.
FIGURE 2 | Main events in cellular entry and trafficking of CoV. Some of the outlined steps were inferred form the SARS-CoV infection of host cells. Figure courtesy
of BioRender.
single-stranded RNA virus with a genome just under 30 kb
(Gordon et al., 2020). SARS-CoV-2 cell entry depends on the
surface glycoprotein, or spike (S) protein common to all CoVs
(Walls et al., 2020; Figure 2). The S protein is comprised of
two functional subunits, S1 and S2, which mediate host-cell
binding and viral entry, respectively (Zhang et al., 2020a). The S1
subunit contains the receptor-binding domain in its ectodomain
(Musarrat et al., 2020), allowing for binding of the virus to host
cell membrane. Once bound, the spike protein is cleaved by host
proteases at the S1/S2 boundary and S2′ site located downstream
of the S1/S2 proteolytic cleavage (Musarrat et al., 2020), priming
the S2 fusion machinery for fusion of the viral and host cell
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membranes (Zhang et al., 2020a). The latter involves formation
of a six-helix bundle fusion core by two heptad repeats (HR1
and HR2 domains) found in each S monomer (Musarrat et al.,
2020). The bundle fusion core forms the initial pore in the
membrane and ultimately leads to membrane fusion (Musarrat
et al., 2020). Cellular entry of SARS-CoV-2, like SARS-CoV,
depends on ACE2 (Gordon et al., 2020; Hoffmann et al., 2020;
Walls et al., 2020; Zhang et al., 2020a), a type I transmembrane
metallocarboxypeptidase that negatively regulates the Renin-
Angiotensin system, and is expressed in the lung, kidney, and
gastrointestinal tract in particular (Riordan, 2003) – all tissues
shown to harbor SARS-CoV (Harmer et al., 2002; Ksiazek et al.,
2003; Leung et al., 2003). Once bound, cellular entry can proceed
in two ways. Firstly, evidence shows that the cellular serine
protease TMPRSS2, also used by SARS-CoV, can prime the S
protein extracellularly (Riordan, 2003) while the virus is bound
to ACE2 (so called “shedding”), allowing for membrane fusion
of the viral membrane and plasma membrane, resulting in direct
viral entry at the plasma membrane. Alternatively, SARS-CoV-2
entry can be facilitated by endosomes; the S protein is primed
by the pH-dependent endosomal protease cathepsin following
viral uptake (Riordan, 2003), leading to fusion of the virus and
endosomal membrane, and the infection. Despite the strong
evidence for endocytosis as a key mechanism for CoV entry,
studies have observed variable mechanisms of entry even when
considering the same CoVs (Yang and Shen, 2020). This is
thought to be due to the use of different cell lines, pointing to
the idea that viral entry is context dependent, including both the
cell type and specific virus features (Meng et al., 2020).
While entry pathways and cleavage patterns seem similar
in SARS-CoV and SARS-CoV-2, some minor differences in
the spike protein of SARS-CoV-2 have been noted, offering
an explanation for the rapid spread of COVID-19. Both CoVs
display an identical furin-like S2′ cleavage site, containing basic
residues necessary for furin mediated fusion, but SARS-CoV-2
has an SPRR insertion at the S1/S2 boundary cleavage site of the
S protein (Meng et al., 2020). As a result of this insertion, SARS-
CoV-2 displays a significantly higher furin score than SARS-CoV
(Meng et al., 2020), attributing to more efficient cleavage of the
spike protein of SARS-CoV-2 that ultimately increases the viruses
pathogenicity (Meng et al., 2020).
Upon successful entry into the cell, the 30 kb SARS-CoV-
2 genome encodes as many as 14 open reading frames (Orfs)
(Gordon et al., 2020). The genome is very similar to SARS-
CoV, with both viruses containing an Orf1ab which encodes
approximately 15–16 predicted non-structural proteins (Nsps)
(Chen et al., 2020). At the 3′ end of the viral genome, as
many as 13 Orfs are expressed from 9 predicted sub-genomic
RNAs, including four structural proteins: Spike (S), Envelope (E),
Membrane (M), and Nucleocapsid (N), and 9 putative accessory
factors (Gordon et al., 2020). The viral genomes differ in some
3′ Orfs, where SARS-CoV-2 possesses an Orf3b and Orf10, which
have limited similarities to SARS-CoV (Gordon et al., 2020). Nsps
and the translated nucleocapsid remain in the cytoplasm, whereas
the remaining structural proteins (S, E, and M) are translated
by ER-bound ribosomes. Following translation, these structural
proteins are incorporated into the ER to form virion precursors
(Schoeman and Fielding, 2019). The virion precursor from the ER
membrane fuse with the genomic material and the nucleocapsid
in the cytoplasm, and are then trafficked out of the cell via small
vesicles (Schoeman and Fielding, 2019), ultimately fusing with
the plasma membrane to complete the cell cycle via exocytosis.
A recent study suggested that SARS-CoV-2 is also able
to spread directly from cell to cell, avoiding the neutralizing
antibodies present in the extracellular space, at a significantly
higher rate than SARS-CoV (Musarrat et al., 2020). This process
is mediated by expression of the S protein on cell surface,
and occurs similarly to fusion that would typically occur
between the viral envelope and plasma or endosomal membrane,
offering an explanation for increased virulence of SARS-CoV-
2 (Musarrat et al., 2020). Cell fusion leads to the development
of multinucleated cells, or syncytia (Musarrat et al., 2020)
whose presence is indicative of membrane fusion. Abl kinase
inhibitors have been found to prevent syncytia formation, and
viral infection by both SARS-CoV and MERS (Sisk et al., 2018).
The Abl kinase signaling pathway is presumably involved in viral
entry, predictably by interfering with actin dynamics required in
virus-cell or cell-cell membrane fusion (Sisk et al., 2018).
Interactions of SARS-CoV-2 proteins have been mapped with
human proteins, whereby 332 high-confidence protein-protein
interactions were identified, that may lead to important targets
for prevention of COVID-19 (Gordon et al., 2020). Most notably,
SARS-CoV-2 interacts with multiple innate immune pathways,
the host translation machinery, a Cullin ubiquitin ligase complex,
and bromodomain proteins. It was observed that various Nsps
target the IFN pathway, the NF-kB pathway, and two E3 ubiquitin
ligases, TRIM59 and M1B1, which are known to regulate anti-
viral innate signaling. This study also identified interactions
between Orf6 and NUP98-RAE1, an interferon-inducible mRNA
nuclear export complex. This proteome interaction of SARS-
CoV affects host interferon signaling by interfering with nuclear
transport (Gordon et al., 2020). It is possible that the effect is
similar in SARS-CoV-2 infection as well. SARS-CoV-2 has also
been observed to interact with the host translation machinery.
CoV mRNAs produce proteins using cap-dependent translation,
thus observed interactions between the viral proteins and the host
eIF4F-cap-binding complex constituents likely play a key role in
viral translation, and provide potential therapeutic targets against
SARS-CoV-2. Many SARS-CoV-2 proteins are also predicted
to be inserted into the ER membrane. This process in SARS-
CoV is mediated by the host Sec61 translocon, and it is
predicted that the process is mediated similarly in SARS-CoV-2
(Gordon et al., 2020).
SARS-CoV-2 interacts with members of a Cullin 2 (CUL2)
RING E3 ligase complex (Gordon et al., 2020). This is common
among viruses that tap into ubiquitin pathways to promote
viral replication and pathogenesis. The Orf10 was shown to
be responsible for binding to the Cullin complex, predictably
hijacking it for ubiquitination and degradation of restriction
factors. Finally, the SARS-CoV-2 envelope, which, as previously
mentioned, resides on ER-Golgi intermediate compartment
(ERGIC) and Golgi membranes, interacts with members of
bromodomain and extra-terminal (BET) domain families, BRD2
and BRD4. These bromodomain proteins play a role in regulating
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gene transcription. A short peptide motif in the NS1 protein of
an influenza A strain interferes with transcriptional processes to
support antiviral response, thus it is possible that this interaction
is responsible for a similar action in the case of SARS-CoV-2 as
well (Gordon et al., 2020).
The largest of the accessory proteins in SARS-CoV, Orf3a,
has been found to play key roles in membrane rearrangement
and host cell death (Freundt et al., 2010). The 3a protein
causes intracellular vesicle formation and is necessary for the
Golgi fragmentation that occurs during viral infection. There
is evidence that Orf3a might disrupt the function of Arf1, a
Golgi regulator protein, leading to increased Golgi fragmentation
(Freundt et al., 2010). Deletion of Orf3a was found to reduce
host cell death after infection with SARS-CoV. It is important
to note that the effects of Orf3a were investigated in SARS-CoV,
but would be worth further investigation and consideration as a
target for SARS-CoV-2.
Interactions between SARS-CoV and valosin-containing
protein (VCP) have been observed, whereby VCP is suggested
to play a role in the maturation of virus-loaded endosomes
(Wong et al., 2015). VCP depletion is associated with inhibited
degradation of the viral N protein, which forms a tight complex
with the RNA genome in mature virions (Wong et al., 2015). This
provides evidence for crucial role of VCP in the release of genetic
material in the cytosol upon viral entry, and could be required for
viral infection (Wong et al., 2015).
EXPERIENCE WITH RNAI THERAPY OF
SARS-COV
While silencing any protein is theoretically feasible using RNAi,
effective target selection is essential for the efficacy of this
approach. RNAi against COVID-19 disease can potentially be
directed against two different categories of targets: (i) viral
proteins essential in survival and replication of SARS-CoV-2, and
(ii) host factors involved in cellular entry and trafficking of the
virus. Below we provide a summary of various molecular targets
considered for RNAi efforts, and current and past experience with
the RNAi based experimental therapy.
Host and Viral Targets for RNAi Therapy
Host Targets
There is increasing evidence on the importance of the endocytic
pathway and the autophagy process in viral entry and replication.
The components of the endocytic pathway has been suggested as
important targets for development of therapeutic strategies for all
species of CoV family (Yang and Shen, 2020). It is still unknown
whether or not the CoV enhance the process of autophagy. In
2012, Bernasconi et al. (2012) reported a novel role for non-
lipidated light-chain 3 (LC3), known as an autophagy protein,
in endoplasmic reticulum-associated degradation (ERAD); CoV
was suggested to hijack LC3 for replication and that silencing
LC3 could inhibit viral replication based on studies performed
on the mouse hepatitis virus (MHV), known as a prototype
CoV. It was previously reported that MHV replication was
impaired in APG5 (another component of autophagy) deficient
embryonic stem cells (Prentice et al., 2004); however, in a more
recent study, no significant difference was reported for SARS-
CoV titers during infection of wild-type or autophagy-deficient
ATG5(−/−) mouse embryonic fibroblasts (Schneider et al.,
2012). The role of autophagy in internalization and replication
of CoV is controversial and remains to be clarified.
The involvement of endosomes/lysosomes in internalization
of CoV was first reported in 1984 for infectious bronchitis virus
(IBV) and porcine epidemic diarrhea virus (PEDV) (Ducatelle
and Hoorens, 1984). Since then, targets in endocytic pathway
has been explored in CoV antiviral therapies. Antimalaria agents
chloroquine and hydroxychloroquine have been studied for
their ability to neutralize lysosomal pH and inhibit protease
activity. While chloroquine was extensively studied in SARS-
CoV (Keyaerts et al., 2004; Vincent et al., 2005; De Clercq, 2006)
and SARS-CoV-2 (Hong, 2020; Millán-Oñate et al., 2020; Moore,
2020), hydroxychloroquine has drawn more interest as a potential
treatment for SARS-CoV-2 alone (Arnold and Buckner, 2020; Yao
et al., 2020; Zhou et al., 2020) or in combination with chloroquine
(Fantini et al., 2020; Meo et al., 2020; Shittu and Afolami, 2020).
It was recently reported that both drugs might interfere with
interaction of SARS-CoV-2 with cell surface gangliosides as well,
which could be additional factors in viral entry into cells (Fantini
et al., 2020). However, this idea remains controversial as there
are reports that show no significant difference in outcome for
patients receiving hydroxychloroquine and the fact that some
COVID-19 patients are already taking this medications as a
prophylactic measure (Parperis, 2020).
The SARS-CoV identified in the original outbreak, and the
new SARS-CoV-2 employ ACE2 as a receptor for S-protein to
facilitate internalization of the virus (Prabakaran et al., 2004).
ACE2 was reported to have a protective role in lungs and it
gets down-regulated after SARS-CoV infection, and therefore
might have a role in pathology of the virus as well (Kuba
et al., 2006). A small clinical study in Wuhan on critically ill
patients showed a worse outcome in patients with hypertension
and diabetes mellitus, which was speculated to be due to
overexpression of ACE2 receptor in alveolar epithelial cells (Rico-
Mesa et al., 2020). On the other hand, it has been shown that
soluble ACE2 has a protective role for many organs including
lungs so that recombinant ACE2 was also suggested as a
therapeutic strategy (Rossi et al., 2020). Proteolytic cleavage of the
ectodomain of ACE2 is performed by 2 different proteases: ACE2
cleaved by TMPRSS2 enhances internalization of SARS-CoV-
2, while Tumor Necrosis Factor-Alpha Convertase (ADAM17)-
cleaved ACE2 offers protection to organs, including lungs (Xiao
et al., 2020). Overall, this seemingly paradoxical roles for ACE2
and the possibility of over-expression of ACE2 as a result of
therapy with ACE inhibitors have ignited discussions over the
benefits and potential risks of targeting ACE2 as a therapeutic
strategy in COVID-19.
Viral Targets
Instead of host targets, targeting viral proteins might be a more
direct (specific) and efficacious approach. In addition to the open
reading frames, the RNA genome contains sections responsible
for expression of the four proteins (S, E, M, and N proteins) that
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can act as RNAi targets (Phan, 2020; Pillay, 2020). S-glycoprotein
received most attention as it plays a major role in cell entry
via ACE2 receptor and antibody binding (Walls et al., 2020).
It is the receptor binding domain (RBD) of S-glycoprotein that
interacts with the peptidase domain of human ACE2 (Li F.
et al., 2005). S-glycoprotein also contains a fusion domain and a
transmembrane domain. Binding of the S-glycoprotein to ACE2
exposes the cleavage sites of the protein to cellular proteases.
Cleavage is performed by transmembrane protease serine 2 and
other cellular proteases and it triggers fusion and endocytosis
(Pillay, 2020). S-glycoprotein is a 150 kDa, highly N-glycosylated
with similarities to the structure of S-protein in SARS-CoV;
out of 14 aa residues in RBD region, only eight are strictly
conserved in SARS-CoV-2. As mentioned, enhanced spreading
efficiency observed in SARS-CoV-2 compared to other β-CoVs
could be attributed to enhanced activity of furin-like cleavage
site in SARS-CoV-2 that facilitates S-protein priming (Rabaan
et al., 2020). The subunit vaccines developed for MERS-CoV and
SARS-CoV (not approved for use in humans) are based on full-
length S-protein, RBD, non-RBD S-protein fragments, and non-S
structural proteins (Wang et al., 2020). Targeting S-glycoprotein
synthesis in host cells via RNAi could potentially reduce the
availability of this protein in host cells for viral assembly, leading
to sub-optimal assembly of the virus and reduced infectivity.
In addition to S-protein, E-, and M-proteins are structural
proteins involved in the formation of viral coat (Wu et al., 2020).
The genome domain responsible for expression of E-protein
is well-conserved. In fact, in a study on mutations among 68
samples of SARS-CoV-2, which identified 42 missense mutations
in all the major non-structural and structural proteins, none was
detected in E-protein (Phan, 2020). The E-protein is an 8–12 kDa
protein and plays a critical role in the virus assembly and release.
It is also involved in ion channel activity that is required for
pathogenesis of SARS-CoV, and possibly SARS-CoV-2 (Rabaan
et al., 2020). The N- and C-terminal of M-protein are ectodomain
and endodomain, respectively. It is found in virion as a dimer
and is involved in maintaining the viral membrane curvature and
binding to nucleocapsids (Neuman et al., 2011). The N-protein
is incorporated into nucleocapsid and each domain can bind to
RNA (Hurst et al., 2009) via its phosphorylated residues.
Industry Focus on RNAi Therapy of CoV
To assess the potential of RNAi in management of COVID-
19, one can inspect the response of pharmaceutical companies
focused on development of RNAi mediated therapies. In the
short time following the publication of SARS-CoV-2 genome,
proprietary designs were implemented by several companies
to identify effective siRNAs and explore the possibility of
such siRNAs for prevention and treatment of SARS-CoV-2
infections. We are aware of this activity through company press
releases since there has not been any time to complete peer-
reviewed studies on silencer designs and efficacy at the time this
review was written. However, the press releases do provide an
indication for the prospect of RNAi approach. Vir Biotechnology
(San Francisco, United States) and Alnylam Pharmaceuticals
(Boston, United States) have reported a joint activity to explore
a library of siRNAs in this disease (Alnylam Pharmaceuticals,
2020). Alnylam reportedly designed and synthesized over 350
siRNAs targeting all available SARS-CoV and SARS-CoV-2
genomes, including targets in highly conserved regions of the
coronavirus RNAs, presumably due to their better retention
in viral progeny (i.e., stable target) and reduced chance of
“inactivating” mutations. The OilX Pharmaceuticals (Suwan,
South Korea) is also pursuing siRNAs that target highly
conserved regions of coronavirus RNA (OliX Pharmaceuticals,
2020). Patent filing was reportedly undertaken that provide broad
composition of matter claims to more than 30 siRNA designs that
target the genome of the COVID virus with highly conserved
regions among CoVs. Specifically, the targets are selected among
the proteins that play important roles in virus replication such as
3CL-protease, RNA-dependent, RNA polymerase, and S-protein.
Sirnaomics (Gaithersburg, United States) (NS Healthcare, 2020)
has also identified potent siRNAs, which target the crucial genes
for CoV infection and replication. All three companies are
interested in inhalational delivery of the siRNA formulations and
a variety of device configurations are likely to be implemented
for inhalational delivery. The relative potencies of the chosen
siRNAs and therapeutic efficacy will be better assessed once
peer-reviewed outcomes are reported in the literature.
Past Experience With siRNA and shRNA
Therapy of CoV
In early studies that utilized siRNA against SARS-CoV
(Hong Kong strain), among the seven sequences used to
target various regions, the most effective ones were two siRNAs
(out of three) directed against the S-protein (Wu et al., 2005). As
in the studies that aimed to inhibit viral binding and explored
effective vaccine epitopes, silencing siRNAs against S-proteins
seems most effective with 85–90% reduction in viral load as
assessed by PCR analysis. An siRNA against the Leader sequence
was relatively less effective (∼50%, estimated) in that study (Wu
et al., 2005). The emergence of the S-protein as a therapeutic
target was also independently verified (Qin et al., 2004; Zhang
et al., 2004) with shRNAs, where one study employed SARS-CoV
infection directly (using strain BJ01).
A separate study focused on a Leader sequence in SARS-CoV
(clone BJ01) that was predicted to be common to all CoV and
expected to undergo minimal mutagenesis, providing a more
stable target for silencing (Wang et al., 2004; Li T. et al., 2005).
This sequence also appeared in the S-protein. An shRNA from a
pDNA expression system was designed against this target whose
delivery ahead of SARS-CoV transfection reduced the viral load.
This study, however, suggested superior effects with targeting
Leader sequence as compared to S-protein gene unlike the
previous cases (Zhang et al., 2004; Wu et al., 2005). Differences
in the silencing efficiencies related to targeting different regions of
the genome as well as the RNAi mode used (i.e., siRNA vs shRNA)
might explain the differences in these results. A study by Ni et al.
(2005) also focused on a non-structural protein 1(NSP1), derived
from the 5′ leader end of the genome. When shRNA transfected
cells were challenged with the SARS-CoV, there was significant
protection of the cells, with PCR based reduction of virus load
being 80-500-fold lower.
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Beyond the 5′ Leader sequences and S-protein gene, targeting
the gene coding for the nucleocaspid N-protein was also explored
with effective reduction of viral loads using the shRNA approach
(Tao et al., 2005; Zhao et al., 2005). It was possible to silence the N
protein in an intramuscular mouse injection model as well using
shRNA approach (Zhao et al., 2005). Recent evidence indicates
that N-protein may act as a viral suppressor of RNAi mechanism
in host cells (Cui et al., 2015), so that its inhibition could enhance
host response indirectly. N-protein was also targeted by Cao et al.
(2011) that utilized 16 isolates of SARS-CoV to choose 3 regions
that were well conserved in the N-genes, providing a better
chance of a universal target. The silencing was implemented with
shRNA in robust 293T cells. It was noteworthy that suppression
of N-gene also resulted in increased INF-β secretion, providing
an additional mechanism to fight the virus.
Lu et al. (2004), Meng et al. (2006), and He et al. (2003) chose
to target highly conserved RNA-dependent RNA polymerase
(RDRP) gene, one of the genes that is conserved in different
strains of CoV, and showed effective silencing of this gene
expression using siRNA and shRNA. There was no synergistic
activity when effective siRNAs were combined in the study of
He et al., 2003, perhaps due to the choice of a single gene
locus for targeting that is not conducive for synergistic activities
(i.e., targeting multiple genes might have allowed synergism).
However, the study noted differential sensitivity of the RDRP
gene to different siRNA sequences, emphasizing the importance
of siRNA design even for individual targets. Viral envelope
E-protein was also targeted with siRNAs (Meng et al., 2006),
but RDRP appeared to be more effective target in reducing
viral replication. It was worthwhile to note that within the
RDRP, widely different efficiencies were noted for several siRNAs
targeting different regions of the gene. The latter was attributed
to better assembly of RISC complex or stability of siRNAs
inside the cells.
M-protein was another target that was explored (Qin
et al., 2007), where the specificity of designed siRNAs were
validated, but no SARS-CoV infection and/or its inhibition
was investigated in that study. A Chinese patent subsequently
claimed pharmaceutically useful formulation with specific siRNA
sequences against M-protein as the basis of a therapy (Ying
et al., 2006). In a more sophisticated study, M-protein gene
from 15 SARS-CoV isolates were compared to identify relatively
stable regions and two specific shRNAs were explored for
silencing. Consistent with previous studies (Qin et al., 2007),
targeting the 3′ portion of M-gene was more effective in reducing
the target mRNA levels. M-protein is also an inhibitor of
the master-regulator nuclear factor kappa B (NF-kB) and its
signaling pathway, which is closely associated with regulation
of inflammatory cytokine secretion. It was not surprising to see
a reduction in INF-β secretion after M-protein silencing (Ying
et al., 2006). The reduction of M-protein synthesis may have
indirect effect in reducing the detrimental inflammatory reaction.
Several accessory proteins with no significant sequence
homology to viral proteins of other CoVs were noted in SARS-
CoV. These proteins derived from subgenomic RNAs were also
effective targets, as effective as the commonly targeted S-protein
(Akerström et al., 2007). It was interesting to note that two or
more mis-match pairing was detrimental for the silencing activity
of the silencer molecules, whereby genomic mRNA with such
base mismatch siRNAs were not silenced. This observation has
important implications for the mutated forms of the virus.
In the most advanced study involving testing on primates
(Rhesus macaque), Li B.-J. et al. (2005) and Tang et al. (2008),
from a new set of 48 distinct siRNAs targeting regions of
entire SARS-CoV genome, identified two leading siRNAs (against
S-protein and ORF1b regions) and delivered them as a mixture
to SARS-CoV-infected fatal Rhesus monkey kidney (FRhK-4)
cells; the siRNAs displayed potent and synergistic activities.
Intratracheal administration of siRNAs were accomplished in
aqueous buffers, D5W (5% dextrose) and Infasurf solution
(i.e., extract of natural surfactant from calf lungs containing
phospholipids, neutral lipids, and hydrophobic surfactant-
associated proteins B in 0.9% aqueous NaCl) along with a
reporter gene to asses silencing efficiency. No special carrier
was needed to implement RNAi. Using the simpler buffer D5W
and a Rhesus macaque model that displayed features typical
of human SARS, intranasal siRNA delivery resulted in effective
lowering of symptoms (based on temperature measurements) in
a prophylactic, co-delivery (with CoV) and postexposure groups,
as well as reduced histopathological changes in the lung tissue of
the treated animals. The replication of the virus was halted (based
on qPCR analysis) typically in three out of four treated primates.
The study provided some guidance about the clinical dose that
may be required with siRNA administration (∼10 mg/kg) but
that is likely to depend on the details of the siRNA formulation
and whether a carrier will be employed along with siRNA.
Critical Issues in Delivery of RNAi Agents
The silencing studies described so far typically employed
liposomal commercial carriers [e.g., Lipofectamine (Wu et al.,
2005), FuGene (Meng et al., 2006) and older generation
lipofection reagents] that are not intended for further animal
studies. Others have used the classical Ca/P mediated transfection
(Wang et al., 2004; Li T. et al., 2005) whose utility for animal
models is not known. No practical carrier emerged in these
studies suitable for clinical applications since most were focused
on demonstrating the target validation with little emphasis on
clinical translation. The cell models used in these studies were
also easy-to-transfect cells such as 293T and Vero cells, whose
features are far different from the primary cells intended for
modification. Without the use of primary cells and animal models
that better represent the clinical scenario, delivery issues to be
faced by RNAi agents in clinical setting will not be solved. To
implement RNAi, most studies concentrated on the shRNA,
where the short interfering RNAs are derived from plasmid-
based expression systems, due to practical aspects of conducting
the initial proof-of-principle studies. This system is convenient
to implement (especially in easy-to-transfect cell lines), more
economical and allows stable expression of interfering RNA
sequences. However, it is unlikely for the shRNA approach to
be employed as a therapy. Most of these studies also focused on
“prevention of infection” whereby the RNAi agents are induced
first and then viral infection is attempted. It is more likely
to demonstrate an efficacy in this kind of a set-up but the
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clinical reality is the reverse; the patients are already infected
with the CoV before the RNAi agents need to be administered.
Although one can envision a prophylactic use of RNAi with stably
integrated shRNA expression systems (if such a system can be
made to turn on gene expression “on demand”), this will probably
not be a clinical reality. One needs to deploy shRNA or siRNA
after the infection and retain the viral load at manageable levels
for the immune system to manage the disease.
It was intriguing to see effective siRNA delivery in a primate
model (Li B.-J. et al., 2005; Tang et al., 2008) even without
the use of a carrier. Our (and others’) extensive cell culture
experience indicates a lack efficacy by naked unmodified siRNA
sequences in the absence of carriers, yet this primate study
observed good anti-viral efficacy without a carrier. The authors
in that study noted that the use of polyethylenimine (PEI)
was associated with lung inflammation in the employed mouse
model, clearly emphasizing the need for a more biocompatible
system in delivery. If a biocompatible carrier could be identified,
it is likely that the effective dose could be reduced below
10 mg/kg, to more acceptable levels as ∼1 mg/kg that was
suggested for systemic injections. Without a carrier, some degree
of degradation is bound to happen (half-life of free siRNA in
serum is generally regarded to be <30 min) so that a “protected”
siRNA should have increased potency. It is likely that the
administered siRNA is “actively carried” into pulmonary cells
by non-specific pinocytosis or macrocytosis. Alternatively, local
biomolecules may complex and present the siRNA for cellular
uptake reminiscent of synthetic carriers. The major soluble
extracellular macromolecules in lungs (e.g., hyaluronic acid,
SPARC) are anionic and are not likely to interact with anionic
siRNA to facilitate uptake. However, with >300 members in the
proteome of lung tissue (Burgstaller et al., 2017), complexing
proteins are bound to be present, even if only cationic domains
participate in siRNA sequestration and cell presentation. Lung
surfactants are another possibility for facilitating siRNA delivery
into the cells (Guagliardo et al., 2018; Autilio and Pérez-Gil,
2019). The surfactants having compositional structure of lipids
(∼90%) and proteins (∼10%) might entrap siRNA with cationic
domains and enhance membrane crossing into the cells due to
lipid components. Our studies on synthetic lipophilic carriers
(Incani et al., 2010) showed that these two domains could be
engineered to obtain effective siRNA delivery agents to a variety
of cells. It may be possible to set-up ECM mimics of pulmonary
tissue (Evans and Lee, 2020) to better understand the mediators of
siRNA delivery into the cells, given the implication of this process
on the potency of siRNAs agents for anti-viral activity.
It is likely that there is no “magic” viral target for most
potent intervention, and several alternative targets might present
itself for silencing. Among the genes encoding for E-, M-,
and N-proteins, a library of 26 siRNA effectively reduced all
three target proteins (albeit at different levels), but siRNAs
with equipotency could be demonstrated against three separate
genes (Yi et al., 2005). It was possible to improve the potency
of less effective siRNAs by enhancing the internal instability
at the 5′-antisense terminal base pair (by adding mis-match
pairs) but this was not attempted to improve the potency
even further.
TABLE 1 | Desirable features of siRNA agents for SARS-CoV-2 therapy.
• Potent antiviral response at <100 nM in cell culture and 1–10 mg/kg
dose in animal models.
• Active after inhalational delivery.
• No homology with the human genome.
• Minimally mutating targets in CoV genome and/or common genome
sequences among CoV family members.
• siRNAs with synergistic activity.
Significant efforts will be required to identify exceptionally
effective RNAi therapy, not only to demonstrate a robust
response but to justify the relatively higher cost of the therapy
as compared to possibly emerging “re-positioned” drugs. The
latter is expected to be <$1,000 per treatment based on our
estimates while the RNAi agents are likely cost significantly
more due to the need for developing a sophisticated (costly)
biomolecule as a drug with an associated delivery system. The
potency is likely to depend on the choice of targeted gene
a priori, followed by specific sequences employed to silence that
particular gene. The resistance development is also likely to
depend on similar factors; the targets that are less amenable to
mutation should be chosen to prevent resistance development
and allow siRNA use among the most patients (given the
more likelihood of finding CoV with similar genomic parts
among the population). Combinational delivery is likely to
play a significant role in potency (KC et al., 2017). Given the
similarity in the physicochemical features of individual siRNA
molecules, it will not be a significant challenge to deliver a
combination of two or more siRNA molecules at the same
time. This is unlike the conventional drugs that display different
physicochemical features due to smaller size and will likely
require separate administration in a patient. The choice of the
combination(s) will be important, and a critical issue will be
whether to target the same gene with multiple siRNAs or to
employ different sets of genes for a comprehensive assault on
the CoV. In this respect, He et al. (2006) explored siRNA
against the full spectrum of viral proteins, where reduction
of 67–83% viral load could be obtained with specific siRNAs
against S-, N-, M-, and E-proteins. More importantly, various
combinations of siRNA targeting different regions of the
genome was synergistically effective to stop viral replication with
greater potency (Table 1).
COV INFECTION AND IMMUNE SYSTEM:
FOCUS ON CYTOKINE STORM
Some of the early studies that noted linkages between specific
SARS-CoV proteins and their role in modulating cytokine
release in cell culture were pointed out earlier. Additionally,
M-protein of SARS-CoV was shown to inhibit NF-kB expression
(in addition to Cox-2) that may contribute to SARS pathogenesis
(Fang et al., 2007). Early production of cytokines and chemokines
in lungs primes the tissue for influx of NK cells, macrophages,
and plasmacytoid dendritic cells (pDC). Such an influx can lead
to a second wave of distinct cytokine and chemokine production
that can further dilate the vasculature and cause pneumonitis
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Uludağ et al. RNAi Against SARS-CoV-2
of the lungs (Chen et al., 2010). Early studies with SARS-
CoV-infected dendritic cells showed low expression of anti-viral
cytokines IFN-α/β/γ and IL-12p40, moderate up-regulation of
proinflammatory cytokines TNF-α and IL-6, but significant up-
regulation of inflammatory chemokines MIP-1α, RANTES, IP-10
and MCP-1 (Law et al., 2005). In macrophages, SARS-CoV failed
to induce anti-viral IFN-α/β gene expression as well (Cheung
et al., 2005). The lack of anti-viral cytokine response despite
chemokine up-regulation could facilitate immune evasion by
the SARS-CoV. Airway and lung memory CD4(+) T cells were
critical in the initial response to SARS-CoV (Zhao et al., 2016).
Interfering with key cytokines could be a fruitful approach to
minimize life-threatening tissue damage in the lungs. Given
the spectrum of altered cytokines, interference with “master”
regulators might be more fruitful rather than late effectors. IL-
17 might be a feasible target in this regard given its central
role in induction of chemokines. In the mouse model deficient
for IL-17RA, viral infection was shown to reduce the immune
cell migration to the lungs, leading to lower morbidity in the
animals. The pro-inflammatory cytokines TNF-α, IL-1β, and IL-
6 were attenuated in IL-17RA deficient mouse, fulfilling the role
of master regulation in this regard. IL-17 was also highly up-
regulated in healthy PBMC infected in vitro with SARS-CoV
(Ng et al., 2004) and one can envision targeting IL-17 with
RNAi agents to attenuate the cytokine storm and minimize the
inadvertent damage. This may be an alternative to antibody
therapy against IL-17 being commercially pursued by Novartis.
One study noted that expression of cytokine genes was
completely absent in PBMC isolated from SARS-CoV patients,
and the immune-related genes which were over-expressed were
usually associated with innate-immune response against bacterial
infection and not viral infection (Reghunathan et al., 2005).
However, this may not reflect the local tissue response. The
PBMCs from healthy individuals did respond to SARS-CoV
infection by early (12 h) cytokine response, including the
involvement of the master regulator NF-kB (Ng et al., 2004) in the
absence of pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6.
As in SARS-CoV infections (Jiang et al., 2005), the systemic levels
of pro-inflammatory cytokine IL-6 was particularly associated
with the severity of SARS-CoV-2 pathology (Zhu et al., 2020)
and anti-IL-6 antibody therapy seems promising in early studies
exploring its utility in the therapy SARS-CoV-2 (Xu et al., 2020).
IL-6 might serve as another target of RNAi agents but whether
targeting a single cytokine among several pro-inflammatory
cytokines will be efficacious enough remains to be seen. Another
chemokine, Interferon-inducible protein-10 (IP-10; also known
as CXCL10) detected in SARS-CoV infections (Jiang et al.,
2005) might be critical since its expression levels was shown
to be associated with disease severity in SARS-CoV-2 patients
(Yang et al., 2020).
The increased mortality among elderly SARS-CoV-2 patients
is well established, whose underpinnings is important to
understand in order to develop an effective therapy for this
patient population. In a primate (cynomolgus macaques) study
comparing gene expression profiles in aged vs young subjects
from lung tissues, the aged subjects displayed higher gene
expressions associated with immune and inflammatory responses
(Wu et al., 2005), while the central transcription factor NF-kB
playing a major role in this response. Two additional cytokines
differentially expressed were IL-8 (up-regulated), as in PBMC
(Jiang et al., 2005), and IFN-β (down-regulated) in aged primates.
IFN-β supplementation attenuated the excess pro-inflammatory
response in aged primates and reduced the disease severity.
This improvement was achieved without changes in viral load
of subjects (Wu et al., 2005), suggesting that addressing viral
load alone might not be absolutely necessary. It might be
possible to augment local anti-viral (with IFN-β like agents)
response without altering the pro-inflammatory processes.
Similar observations were noted in a mouse model, where adult
Balb/c mouse displayed a greater cytokine response to SARS-
CoV infection compared to young mice (Zhu and Qu, 2009).
Endonuclease (EndoU) region incorporated in the non-structural
protein 15 (nsp15) domain of CoV, seems critical to suppress the
initial IFN-β response (Kindler et al., 2017), and RNAi agents
targeting this region might suppress viral load while inhibiting
the viral attempts to dampen the host anti-viral response.
A generic approach to control cytokine storm is to employ
corticosteroids. Recent evidence from a meta analysis indicated
that corticosteroid use was associated with delayed virus clearing,
no significant reduction in deaths, prolonged hospitalization
and use of mechanical ventilation increased (Li et al., 2020).
The efficacy of the non-steroidal anti-inflammatory drugs, the
inhibitors of cyclooxygenase (COX) 1 and 2, are also not known
even though indomethacin was shown to reduce SARS-CoV
replication in dogs (Amici et al., 2006). S-protein in SARS-CoV
could activate the inducible COX-2 (Liu et al., 2007) but whether
COX-2 inhibition results in an effective therapy remains to be
determined. Perhaps more specific interference with the specific
mediators of cytokine storm might provide a more desirable
outcome, but this remains to be seen.
INHALATIONAL DELIVERY
Inhalation delivery of drugs and vaccines, both oral, and
nasal, has been introduced as an alternative to conventional
delivery approaches with many advantages including ease of
administration and rapid onset of action. Pulmonary delivery
has been used for localized and systemic delivery of various
drugs such as peptides, proteins, DNAses and vaccines (Bhavane
et al., 2003; Velasquez et al., 2011). Live attenuated influenza
vaccines, which have been available as inactivated form since
1940s through intramuscular, was introduced in US in the form
of nasal spray in 2003. More attention has been recently given to
nasal inhalations of vaccines since this route can provide better
mucosal immune responses (Fiore et al., 2009). The mucosal
immunity is critical in providing protection against pathogens
localized in mucus membranes as a result of entry through
nose or mouth. The immunity from localized formulation better
encounter and neutralize the pathogens at the point of entry
before they enter the systemic circulation (Yusuf and Kett,
2017). Nasal formulations in the market are mainly in the
form of drops, liquid sprays, powder sprays or gels. Drops
are the most common formulations and require either tilting
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FIGURE 3 | Different approaches to vaccine development against COVID-19 disease. Main strategies are schematically shown, which relies on (from top left,
clockwise) (i) nucleic acid (DNA and RNA) vaccines delivered with nanoparticulate carriers and coding for specific viral sub-units or virus-neutralizing agents, (ii) direct
administration of DNA/RNA expression systems with forced expression, (iii) viral vaccines composed of recombinant or attenuated viruses, (iv) vaccines derived from
recombinant viral proteins or purified sub-unit proteins, and (v) cell based vaccines relying of modification and administration of cells. Figure courtesy of BioRender.
back the head or laying down to prevent leaking out and to
ensure that the droplets of liquid remain in the nasal cavity.
This could be challenging in animal studies and large human
vaccination settings. Gels and sprays could overcome this issue
since the gelling and mucoadhesive agents in the formulations
would prevent leaking out of nostrils. Powder formulations could
provide more stability compared to liquid formulations, and may
be delivered deeper in the nasal cavity (Yusuf and Kett, 2017).
Nanoparticle formulations have recently garnered more attention
for their ability to ability to deliver a range of therapeutic agents,
including nucleic acids and RNAi agents.
Inhalational delivery of RNAi agents and dry powder
formulations of siRNA was recently reviewed (Dua et al.,
2019; Keil and Merkel, 2019). In 2020, Fukushige et al. (2020)
described hyaluronic acid coated liposomes as spray freeze-dried
nanoparticles for pulmonary delivery of siRNA in lung cancer
as a superior alternative to non-modified liposomes. Intranasal
inhalation of a formulation comprising of ovalbumin and an
immunoadjuvant loaded in poly(lactic-co-glycolic acid) (PLGA)
nanoparticles induced more robust antigen-specific CD8 + T-cell
responses in comparison to intraperitoneal administration of the
same formulation (Li B. et al., 2016). Chitosan is another polymer
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used extensively in inhalation therapy due to its mucoadhesive
properties either as the carrier or coated on the surface of other
nanoparticles. Chitosan was used to encapsulate the influenza
vaccine in dry powder formulations for inhalation therapy. The
result supported the appropriateness of the dry powder chitosan
nanoparticles for nasal delivery owing to the mucoadhessive
property of chitosan and the nano size range of the formulation
(Muralidharan et al., 2015). The pulmonary surfactant Curosurf-
coated on nanoparticles was also used to enhance the inhalation
delivery siRNA; SP coating enhanced the nanoparticle uptake
by alveolar macrophages, which are the main targets in the
treatment of inflammatory pulmonary diseases (Merckx et al.,
2018). Finally, we note that a recent study showed that siRNA
inhalation alone (without a carrier) appeared to be as effective
as siRNA formulated with the traditional polymeric carrier PEI,
perhaps suggesting the unique features of inhalational route to
sustain “free” siRNA activity (Ito et al., 2019).
FUTURE PERSPECTIVES
The rapidly changing literature on SARS-Co-2 makes it difficult
and, at the same time exciting, to predict future developments
on the use of RNAi agents for managing the COVID-19 disease.
It is generally agreed that effective COVID-19 vaccines will be a
permanent solution to viral infections and numerous strategies
are developed to this end (Figure 3). It is likely that more than
one strategy could be successful to this end, some strategies
might be more suitable for certain patient populations and that
the nature of viral evolution might hamper effective vaccine
development efforts (for reviews on COVID-19 vaccine, see
Conte et al., 2020; Pandey et al., 2020; Wang et al., 2020). It is also
likely that the immunizations might not be permanent and that
some individuals could not develop the required immunization
at all. Drug therapies and therapies based on RNAi could be
an alternative in less than desired vaccination outcomes. At
the time of writing of this manuscript, no therapeutic RNAi
studies were reported on SARS-CoV-2 silencing, so that we
relied on past experience with similar CoV infections to shed
light on critical issues and fruitful avenues that may be possible
in the future. Potential siRNA sequences against SARS-CoV-2
genome are beginning to be reported in the literature (Chen
et al., 2020), but their validation remains to be tested. Besides
the role of known mediators summarized above, SARS-CoV
encodes numerous accessory proteins whose importance in
natural infection process is currently unclear (Chen and Zhong,
2020). Some of these proteins could be used as additional targets
for RNAi mediated silencing, but their importance remains to be
explored. Table 2 summarizes some of the CoV targets whose
importance as RNAi target remains to be explored. Beyond the
viral targets, host factors might also provide opportunities for
RNAi agents. It is likely that targeting host factors might be
more likely to lead to undesired effects from RNAi agents, but
they could provide alternative targets in the fight against SARS-
CoV-2. Mechanistic insights as outlined in section “Mechanism
of Cell Entry and Infection for SARS-CoV-2” can provide
individual targets worthwhile to pursue, but a more fruitful
TABLE 2 | Other potential targets (from SARS-CoV) for silencing and their
perceived function.
• ORF-9b: Mitochondrial manipulation to limit IFN response (Shi
et al., 2014).
• Papain-like Protease (PLpro): Up-regulation of TGF-β1 mediated
pro-fibrotic responses (Li S.-W. et al., 2016).
• ORF-3a, ORF-4a: May function as ion channel that may promote
virus release (Lu et al., 2006; Zhang et al., 2014).
• Non-structural Protein 15 (nsp15): Anti-apoptotic function by
inhibiting MAVS-induced apoptosis (Lei et al., 2009).
• Viral 7a Accessory Protein: Suppression of host silencing (Karjee
et al., 2010).
• Protein 6: Blocks nuclear import of macromolecules from
cytoplasm (Hussain et al., 2008).
approach could be deliberate (non-biased) RNAi screens that
could rank the importance of various targets and yield leads
with relative ranking of their efficiency. Studies toward this
goal, a common approach in anti-cancer therapies, was recently
reported with SARS-CoV and identified dozens of promising
host factors for silencing and reduction of viral load (Dirmeier
et al., 2020). Similar lines of enquiry with SARS-CoV-2 remains
to be reported and it will be so important to identify if the
critical host factors are common in the case of both types of
viruses. In this case, our confidence to translate the know-
how generated from the SARS-CoV to the SARS-CoV-2 will be
greatly enhanced.
Past investigations on non-coding microRNAs (miRs) have
opened up new possibilities particularly into development of
malignancies and their therapy, but this remains a vastly
understudied area in the case of SARS-CoV. The significant
changes in endogenous miR profiles of cells transfected with
porcine hemagglutinating encephalomyelitis virus (HEV), for
example, have been noted (Fan et al., 2020; Hu et al., 2020).
miR-1246 was recently linked to regulation of ACE2 expression
in airway epithelium (Zhang et al., 2020b) and several miRs
have been predicted to bind to the SARS-CoV-2 genome (Chen
and Zhong, 2020). Such miRs could serve as RNAi targets
and/or might be deployed directly (either as miR mimics
or anti-miRs), or indirectly as a result of modulation with
pharmacological agents. Identifying the pertinent miRs and
revealing their mechanistic involvement is bound to provide
effective leads not predicted before, such as the case of Syndecan
1 involvement, which is regulated by miR-10a-5p, and whose
mimic significantly altered the course of HEV replication
(Hu et al., 2020).
While the scientific rationale may identify optimal targets,
intellectual property considerations might as well determine the
target choice for individual pharma companies to better navigate
the drug development process without infringement. If cancer
experience was to serve as a guide in this effort, we think that
targeting alternative genome regions might be more fruitful
especially if CoV might get to heavily rely on certain biomolecules
for replication in the face of drug assault, which might be
its Achilles heel. We, and others, observed that cultivating
transformed cells in the presence of drugs allow rapid resistance
development, but the cells become “too” reliant on certain
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mediators, such as anti-apoptotic proteins, whose silencing with
RNAi makes them exceptionally sensitive to conventional drug
and/or siRNA treatments (Aliabadi et al., 2013).
Finally, one must consider the safety of siRNAs in reaching
the desired treatment target. It is possible to design CoV-specific
siRNAs with no “theoretical” cross-reactivity to human genome,
but this issue remains to be validated. Partial homology and
resulting hybridization to non-target mRNAs might lead to toxic
effects so that potency vs safety issues might have to be weighted
in choosing the final formulation. Inhalational delivery is bound
to aid in minimizing the safety concerns, since less drug doses
might have to be delivered to the critical site of viral infection
(i.e., lungs). Respiratory complications due to deposition of a
foreign material in the airways is always a concern but the
benefits of direct inhalational delivery are likely to overweight
its shortcomings. At the present time, no inhalational delivery
of RNAi agents against CoV have been reported, but this is
bound to change in the near future. Various technologies seem
to be in place for dry powder and liquid formulations, as well
as mucoadhesive formulations for this end, and siRNA and
pDNA (to code for shRNA) are now being incorporated into
such formulations with functionally active form. Different lines
of attack are anticipated against SARS-CoV-2 in the near future
with different degree of success.
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